Analytik Jena AG : Analytik Jena Announces Financial Figures for the First Quarter 2012/2013

  Analytik Jena AG : Analytik Jena Announces Financial Figures for the First
                              Quarter 2012/2013

Analytik Jena AG / Analytik Jena Announces Financial Figures for the First
Quarter 2012/2013 . Processed and transmitted by Thomson Reuters ONE. The
issuer is solely responsible for the content of this announcement.

  oOperating profit below expectations at EUR 1.23 m
  oTotal revenue growth of 4.9 % satisfactory and heavily influenced by the
    Analytical Instrumentation core business
  oRevenue growth of 19.5 % in Asia reinforces market positioning
  oNegative financial result due in particular to currency effects

Jena (Germany), February 14, 2013 - Analytik Jena AG (Prime Standard: AJA,
ISIN: DE0005213508) hereby announces the final figures for the first quarter
of the 2012/2013 financial year. According to the figures, the manufacturer of
laboratory, bioanalytical and analytical measuring technology generated
consolidated revenue of EUR 24.31 m (previous year: EUR 23.18 m), thus
achieving a year-on-year revenue upturn of 4.9 %. The Group achieved an
operating profit of EUR1.23 m (previous year: EUR 1.89 m), despite the
challenging environment. Due especially to currency effects and a negative
contribution to earnings from the 49.0 % subsidiary AJZ Engineering, the Group
posted a consolidated net loss for the period of EUR -0.04 m (previous year:
EUR 1.46 m). Earnings per share amounted to EUR-0.01 (previous year:
EUR0.25).

"Analytik Jena AG began the new financial year 2012/2013 with growth in
consolidated revenue. Nevertheless, we are not satisfied with our earnings in
the quarter. In the first few months of the new financial year, we posted some
weaker revenue and gross margins of subsidiaries, while we also had to
compensate for exchange rate influences. Even continued strong and growing
business in China and the Far East did not balance this out", said Klaus
Berka, CEO of Analytik Jena AG. "Nevertheless, we anticipate that this weaker
start to financial year 2012/2013 will balance itself out over the course of
the period as a whole, and that we will again achieve our aim of finishing the
year with increased revenue and earnings in our operating business."

Revenue Development and Segments

Segment performance presented a mixed picture. While the Analytical
Instrumentation unit again showed itself to be a strong pillar of the Company
and generated solid year-on-year revenue growth of 11.9 % to EUR 15.77 m
(previous year: EUR 14.09 m), in the Life Science segment - which currently
still focuses much more intensively on the European and American markets and
is thus confronted with the negative economic influences more heavily in
comparison - revenue declined by 7.5 % to EUR 7.35 m (previous year: EUR 7.95
m). Especially the two subsidiaries Biometra GmbH and CyBio AG, despite still
showing positive operational figures, generated weaker revenue and earnings,
while business unit revenue in the parent company was raised by 29.6 %. The
Optics unit posted slight revenue growth of 4.5% to EUR 1.20 m (previous
year: EUR 1.14 m), but was also forced to absorb higher costs due to high
expenditure for OEM product manufacturing. In Optics, the IWA exhibition
taking place in Nuremberg at the beginning of March is expected to have a
significant positive effect.

Considered in terms of regions, the Asia region made the most significant
contribution to revenue growth for the Analytik Jena Group. In Asia, revenue
increased from EUR 7.81 m to EUR 9.33 m year on year, a rise of 19.5 %. In
Germany and the rest of Europe, revenue was also up slightly by 2.8 % and 2.5
% respectively, while revenue in America fell considerably by 27.4 %. The
export share increased slightly to 70.7% in the first three months of the new
financial year (previous year: 70.1%).

Earnings

Operating profit of the Analytik Jena Group totaled EUR1.23m in the first
quarter (previous year: EUR1.89m), which was 35.2% lower than that achieved
in the same period of the previous year. The EBIT margin declined accordingly,
falling from 8.2% to 5.0%. Analytik Jena AG posted earnings before interest,
taxes, depreciation and amortization (EBITDA) of EUR2.26m in the past
quarter (previous year: EUR2.89m), which is equivalent to a decline of
21.7%. Owing to the unfavorable development of the USD and YEN and the
resulting exchange rate losses (compared to exchange rate gains in the same
period of the previous year), as well as a negative result from the investment
in subsidiary AJZ Engineering, the financial result was impacted negatively.
Analytik Jena thus posted earnings before taxes (EBT) of EUR -0.06 m (previous
year: EUR 2.06 m). Overall, the Analytik Jena Group posted a consolidated net
loss for the period of EUR-0.04m (previous year: EUR1.46m). Earnings per
share amounted to EUR-0.01 (previous year: EUR0.25).

Changes in Statement of Financial Position

The Group's total assets as of the balance sheet date on December 31, 2012
fell slightly by 3.3 % to EUR 102.17 m (September 30, 2012: EUR 105.65 m). In
the reporting period, Analytik Jena showed almost unchanged equity of EUR
46.16 m (September 30, 2012: EUR 46.25 m). The equity ratio rose accordingly
from 43.8% as of September 30, 2012 to 45.2% as of December 31, 2012. Cash
and cash equivalents totaled EUR 20.34 m as of the end of the reporting period
(September 30, 2012: EUR 21.53 m). At the same time, Analytik Jena recorded
operating cash flow of EUR 1.57 m in the reporting period.

Human Resources

As of the balance sheet date, the Group employed 815 staff, including 46
trainees (previous year: 807 employees, including 39 trainees).

Outlook

Development in the Analytical Instrumentation business unit will largely
depend on the future global economic situation, whereby the largest growth
prospects exist in developing and emerging countries, above all China, where
Analytik Jena AG has an excellent market position. However, steadily rising
costs in China and a growing currency risk must also be taken into
consideration. Irrespective of these variables, the Executive Board expects
stable business in this core area overall.

The Company expects revenue and earnings to stabilize in the Life Science
business unit. The subsidiaries, including Japan, are anticipated to
contribute to this as well as China.

In the Optics consumer segment, which has not yet returned to its former
strength, the Company's main focus is on expanding the new OEM business area
as well as traditional observation optics and optical sights. By tradition,
the IWA leading exhibition held in Nuremberg at the beginning of March will
once again have a significant positive effect on order and revenue development
in the segment in the current financial year. Thanks also to a series of new
or modified products, Analytik Jena expects this unit to regain momentum.

The Company anticipates a stable second quarter overall. As is usual, Analytik
Jena will announce its outlook for the entire financial year at the Annual
General Meeting on April 23, 2013.

Further Information

The full financial report can be accessed at
http://berichte.analytik-jena.de/3-MonthReport_1213.pdf.

Contact:
André Muehlig
Analytik Jena AG
Konrad-Zuse-Strasse 1
07745 Jena/Germany
Tel. +49 3641 779281
Email: ir@analytik-jena.com

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Analytik Jena AG via Thomson Reuters ONE
HUG#1678125

--- End of Message ---

Analytik Jena AG
Konrad-Zuse-Straße 1 Jena Germany

WKN: 521350 ;ISIN: DE0005213508;Index:Prime All Share;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
 
Press spacebar to pause and continue. Press esc to stop.